Protein Degeneration Therapy Market Size & Share, by Application (Inflammatory, Neurology, Oncological, Respiratory); Route of Administration (Oral, Intravenous); Product Type (Degronimids, Immuno-modulatory Imide Drugs (IMiDs), Selective Androgen Receptor Degraders (SARD), Selective Estrogen Receptor Degraders (SERD), Specific Bromodomain and Extra-Terminal Motif (BET), DUB Inhibitors, PROTACs) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3968
  • Published Date: Feb 05, 2024
  • Report Format: PDF, PPT

Companies Dominating the Protein Degeneration Therapy Market

top-features-companies
    • F. Hoffmann-La Roche AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • Amgen Inc.
    • Baxter International Inc.
    • Eli Lilly and Company
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Sanofi SA

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Amgen Inc. teamed up with Generate Biomedicines to identify and develop protein therapies for five targets, help multi-specific drug design even more, and create prospective lead compounds with predictable manufacturability and clinical behavior. In addition, by combining Amgen's biologics drug discovery expertise with Generate's AI platform, they can further shorten drug discovery timelines and could generate over USD 1 billion for the Flagship Pioneering spinout.
  • Eli Lilly and Company collaborated with Lycia Therapeutics, Inc. to address critical unmet medical needs in Lilly's therapeutic areas of focus, such as immunology and pain, and use cutting-edge new technology to tackle difficult illness areas such as immunology and pain. Further, this collaboration will enable the development of many therapeutic modalities, including antibodies and small compounds.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3968
  • Published Date: Feb 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing burden of cancer across the globe and the growing advancements in protein degenration therapy are the major factors driving the growth of the market.

The market size of protein degeneration therapy is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2024-2036.

The major players in the market are Baxter International Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and others.

The oral segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying